Dube Eric M 4
4 · Travere Therapeutics, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) CEO Eric Dube Sells Shares
What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), reported sales and awards. On Feb 3, 2026 he sold 66,452 shares at $32.06 ($2,130,451) and 33,635 shares at $32.70 ($1,099,865) — a total of 100,087 shares for roughly $3.23 million. On Jan 31, 2026 he was granted restricted stock units (RSUs): 113,800 RSUs and 303,600 RSUs (the latter reported as a derivative award). The RSU grants show an acquisition price of $0.00 (typical for awards).
Key Details
- Transaction dates: RSU grants dated 2026-01-31; sales executed 2026-02-03.
- Sales breakdown: 66,452 shares @ $32.06 = $2,130,451 (weighted avg $32.06; range $31.52–$32.52); 33,635 shares @ $32.70 = $1,099,865 (weighted avg $32.70; range $32.5248–$32.88). Total proceeds ≈ $3,230,316.
- Grants: 113,800 RSUs + 303,600 RSUs = 417,400 RSUs (each RSU = right to one share on vesting).
- Footnotes: Sales were made under a written 10b5-1 trading plan adopted June 16, 2025; the sale included shares sold to cover tax withholding on RSU vesting. Standard option vesting schedule referenced (1/4 at first anniversary, then monthly over 36 months).
- Shares owned after transaction: Not specified in the provided filing.
- Filing timeliness: No late-filing flag indicated in the provided data.
Context
The sales were executed under a pre-established 10b5-1 plan and included shares to cover taxes on vested RSUs, which is a common, routine reason for insider stock sales. This filing reports both awards (RSUs) and routine disposals; purchases would generally be considered a stronger bullish signal than routine sales.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-31+113,800→ 532,973 total - Sale
Common Stock
[F2][F3]2026-02-03$32.06/sh−66,452$2,130,451→ 466,521 total - Sale
Common Stock
[F2][F4]2026-02-03$32.70/sh−33,635$1,099,865→ 432,886 total - Award
Employee stock option (right to buy)
[F5]2026-01-31+303,600→ 303,600 totalExercise: $33.09Exp: 2036-01-31→ Common Stock (303,600 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- [F2]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F3]The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F4]The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F5]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.